Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m…
Read More
Xeltis
De Lismortel 31
5612 AR Eindhoven
The Netherlands
info@xeltis.com
+31 40 751 7614
Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency…
Read More
Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate…
Read More
Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP)…
Read More
Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement EINDHOVEN, The Netherlands, 11…
Read More
Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2…
Read More
Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages…
Read More
Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership…
Read More
Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows…
Read More
aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent,…
Read More